2012-07-25

Fosun Pharma selected into the Top 20 Most Competitive Pharmaceutical Listing Companies in China

Recently, the fourth session of poll of China Top 20 most competitive pharmaceutical listing companies in sponsored by China Pharmaceutical Corporation Management Association and organized by Medical Manager Magazine and Hejun Consulting Group and 2012 Poll of the Top 10 pharmaceutical listing companies with most investment value were announced in Beijing. With competitive performance and good reputation, Fosun Pharma was re-elected to “Top 20 most competitive pharmaceutical listing companies in China” by ranking the fifth of the total score. Fosun Pharma has been selected into the ward roll for three consecutive times.

The competitiveness poll of Chinese pharmaceutical listing companies has been the four time this year. With scientific and rational evaluation system, objective and fair selection process and strongly-oriented selection results, it has been recognized and positively evaluated by many listed companies and the industry. The tracking results of the poll over the first two years show that the pharmaceutical listing companies selected have shown rapid growth and feedback value for shareholders. In 2009, the average rate of return of the first Top 20 most competitive pharmaceutical listing companies was 28.12 percent and the average rate of return of the first Top 10 pharmaceutical listing companies with most investment value was 37.95%; in 2010, the average rate of return of the second Top 20 most competitive pharmaceutical listing companies was 28.41 percent and the average rate of return of the second Top 10 pharmaceutical listing companies with most investment value was 36.60%, both significantly surpassing the overall rate of return of the corresponding A-share broader market and the pharmaceutical sector.

This poll was launched in March, 2012, which lasted four months to make an analysis of financial statement of 193 Chinese pharmaceutical companies with the annual sales amount of more than RMB 100 million listed in Shanghai, Shenzhen, Hong Kong, Singapore, New York and Nasdaq. The company’s sales revenue, profit, total market value and sales growth, profit growth, market value growth, return on net assets, asset-liability ratio and liquidity ratio over the past year as the basic data, the industrial dimension, management dimension and capital dimension are constituted, and then the weighted score is calculated, accounting for 68% of the total score of the poll. The rest? accounting for 32% of the total selected score, is constituted of the dimension of manager(manager quality, management team) and resource dimension(shareholders' resources, uniqueness), which was completed by industry experts, senior securities analysts and mainstream financial media reporters by questionnaire scoring and consolidation.

Seen from the market performance, pharmaceutical listing companies achieved the operating income of RMB 402.864 billion in 2011, with an year-on-year increase of 20.22%, achieved the total profit of RMB 45.693 billion, with an year-on-year increase of 14.28%; the net profit attributable to the parent company was RMB 35.712 billion, with an year-on-year of 12.41%; after non-recurring gains and losses were deducted, the net profit was 28.921 billion, with an year-on-year increase of 0.25%. Although the overall growth of pharmaceutical companies remained stable, the profit growth has obvious signs of slowing, which is influenced by the macroeconomic environment and, more importantly, attributes to pressure caused by drug price reduction, centralized drug purchase and other industry policy controls. Weakened profitability ultimately resulted in the pharmaceutical sector to decrease 24.38% as a whole, underperforming the broader market by 4.9 percentage points; compared to a good performance in 2010, pharmaceutical listing companies can be described as experiencing a decreasing process one stage by one stage over the past year.

Overall weakening of the industry performance is an excellent test opportunity for the company's competitiveness, and thus the Top 20 most competitive e pharmaceutical listing companies ultimately selected, as a leader in various sub-sectors of the pharmaceutical industry will become the main force of overall performance of the pharmaceutical sector within a quite long time as I believe.

The Top 20 most competitive e pharmaceutical listing companies cover the major sub-sectors of the pharmaceutical industry, such as chemical raw materials, chemical preparations, proprietary Chinese medicines, bio- pharmacy, medical devices and pharmaceutical circulation, etc. Since a considerable part of listed company business areas cover more than one sub-sector, it is very difficult to break down these companies in terms of industry. However, the strong position of the Chinese medicine listed companies was overall unchanged in the roll of the top 20 most competitive e pharmaceutical listing companies this year; in addition, a new force of listed companies in the medical device industry and health care services suddenly rises.

Retrospecting the 4th pharmaceutical listing company competitiveness poll, it is not difficult to find that a group of leading companies with excellent qualification, steady growth and rich potential have been consecutively selected to the roll. Yunnan baiyao, Hengrui Medicine, Kangme Pharma, Dong EE Jiao and Tasly have been selected to the roll for four consecutive times; Fosun, Mindray Medical, China BioPharma and Sinopharm have been selected to the roll for three consecutive times, which fully embodies firm industry competitiveness of these companies.

sitemap网站舆图